Pregnancy
Conditions
Keywords
Misoprostol, Induction, Foley
Brief summary
A randomized, prospective trial will be offered to women admitted to the Roosevelt Hospital labor floor for labor induction. The hypothesis is that the simultaneous use of a foley bulb together with vaginal misoprostol will result in shorter induction to delivery time compared with vaginal misoprostol alone
Detailed description
1. Objectives The hypothesis is that cervical ripening using a foley bulb together with vaginal misoprostol (cytotec) will result in shorter induction to delivery time compared with vaginal misoprostol alone 2. Background The rate of induction of labor in the United States is approximately 20% of all births. Induction of labor can result in prolonged labor and increases the rate of cesarean delivery, both of which are associated with increased maternal and neonatal morbidity. Ripening of an unfavorable cervix has become an integral part of the labor induction process. The best method of cervical ripening remains controversial; no one method has proved to be superior. Women requiring labor induction often present with unfavorable cervices which can lead to a prolonged induction. Cervical ripening is often done to increase the likelihood of successful labor induction. Misoprostol (cytotec) is PGE1 analog and widely used for cervical ripening and is the preferred method of induction of labor based on the safety reported literature. Low-dose (25 mcg) intravaginal misoprostol appears to be safe and effective for cervical ripening in term pregnancy for patients without a history of cesarean section. Compared with other cervical ripening methods, misoprostol has an increased rate of vaginal delivery within 24 hours without significant differences in cesarean section rates or fetal outcomes. The use of the foley catheter for induction of labor was first described by Krause in 1953. In 1967 Embrey and Mollison reported a 94% successful induction rate after using the foley catheter for cervical ripening. Since then, several studies found transcervical foley catheters as effective as prostaglandins preparations for ripening without an increased risk of uterine rupture. There are many proposed methods for induction of labor including mechanical (transcervical foley bulb) and chemical methods (prostaglandins, oxytocin). A number of randomized trials have compared the use of foley bulb, oxytocin and misoprostol in different combinations for induction of labor and their results are contradictory with regards to induction to delivery time, successful vaginal delivery and labor complications. There are two studies that evaluated the foley bulb with misoprostol comparing to misoprostol alone. Carbone el al study, found the mean induction to delivery time was 3 hours shorter with the combination of the foley bulb and vaginal misoprostol when compared to vaginal misoprostol alone. In a study by Chung et al, there was no difference in the induction to delivery time. Therefore given the contradicting results regarding induction of labor using foley bulb with misoprostol or misoprostol alone, the purpose of our study is to determine if there is a decrease in the induction to delivery time with one method versus the other. 3. Setting of the Human Research Research will take place on the labor and delivery floor of Roosevelt Hospital 4. Study Design a) Recruitment Methods Women admitted to labor and delivery at Roosevelt Hospital will be asked to participate in the study if they are to have an induction of labor at or beyond term (37weeks of gestation). Patients will be screened and those meeting the eligibility criteria will be approached. Informed consent will be obtained. After a discussion about the study with an eligible interested subject, an investigator will review the consent with them. The investigator will give the potential subject the opportunity to ask any questions and have them answered. Potential participants will be given the opportunity to think about the study. (Only those investigators listed as study personnel and authorized to obtain consent, will obtain informed consent). Once a patient wishes to join the study and informed consent is obtained, the subject can participate. Each subject will receive a signed copy of the consent form. The subject can withdraw from the study at any time without any retribution.
Interventions
25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
Sponsors
Study design
Eligibility
Inclusion criteria
* Term 37 weeks or more, singleton in cephalic presentation * Age 18 years and older * Patient admitted for induction of labor
Exclusion criteria
* Malpresentation * Preterm labor less than 37 weeks of gestation * Patients with fetal anomalies * Premature rupture of membranes * If the cervix is closed and unable to place the foley bulb * Multiple gestation * Non-reassuring fetal heart tracing * Contraindication to misoprostol * Contraindication to vaginal delivery (i.e. placenta previa, vasa previa, active vaginal bleeding, marginal previa, macrosomia, etc). History of prior uterine surgery such as cesarean section or myomectomy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Per Treatment Protocol: Time (Hours) From Induction to Delivery | day 1 | — |
| The Time Interval From Induction to Delivery: All Participants | Day 1 | During labor from the start of the induction to the delivery |
| Time (Hours) From Induction to Delivery: Nulliparous | Day 1 | — |
| Time (Hours) From Induction to Delivery: Multiparous | Day 1 | — |
| Time From Induction to Delivery: VD | Day 1 | Time (hours) from induction to delivery: Vaginal Delivery (VD) |
| Time From Induction to Delivery: CD | Day 1 | Time (hours) from induction to delivery: Cesarean Delivery (CD) |
Secondary
| Measure | Time frame |
|---|---|
| The Time From Induction Until to Active Phase Labor | Day 1 |
| The Time From Active Phase to Delivery | Day 1 |
| Incidence of Chorioamnionitis | Day 1 |
| Incidence of Uterine Tachysystole | Day 1 |
| Incidence of Patient Discomfort | Day 1 |
| Estimated Blood Loss | Day 1 |
Countries
United States
Participant flow
Recruitment details
During the study period from September 2015-July 2016, 4767 patients delivered at Mount Sinai West and of these, 1423 deliveries followed induction of labor. A total of 200 patients consented to participate in the study and were randomized, 100 to each group.
Participants by arm
| Arm | Count |
|---|---|
| Misoprostol Group 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist.) | 100 |
| Misoprostol and Foley Bulb Group 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter. | 100 |
| Total | 200 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | did not receive foley | 0 | 1 |
| Overall Study | labor after randomization | 0 | 4 |
| Overall Study | received foley | 8 | 0 |
| Overall Study | vaginal bleeding | 0 | 1 |
Baseline characteristics
| Characteristic | Misoprostol Group | Misoprostol and Foley Bulb Group | Total |
|---|---|---|---|
| Age, Continuous | 31.5 years STANDARD_DEVIATION 5.9 | 31.8 years STANDARD_DEVIATION 6.3 | 31.6 years STANDARD_DEVIATION 6.1 |
| Anesthesia General Anesthesia | 0 Participants | 3 Participants | 3 Participants |
| Anesthesia Neuraxial anesthesia | 96 Participants | 91 Participants | 187 Participants |
| Anesthesia None | 4 Participants | 6 Participants | 10 Participants |
| Bishop score at misoprostol placement | 2.71 units on a scale STANDARD_DEVIATION 1.78 | 3.17 units on a scale STANDARD_DEVIATION 1.94 | 2.9 units on a scale STANDARD_DEVIATION 1.8 |
| BMI | 31.8 kg/m^2 STANDARD_DEVIATION 6.8 | 31.22 kg/m^2 STANDARD_DEVIATION 5.7 | 31.56 kg/m^2 STANDARD_DEVIATION 6.3 |
| Gestational age at delivery | 39.4 weeks STANDARD_DEVIATION 1.4 | 39.6 weeks STANDARD_DEVIATION 1.3 | 39.4 weeks STANDARD_DEVIATION 1.4 |
| Indication for induction Advanced maternal age | 1 Participants | 4 Participants | 5 Participants |
| Indication for induction Gestational diabetes/Diabetes | 11 Participants | 11 Participants | 22 Participants |
| Indication for induction Hypertensive disorder | 28 Participants | 20 Participants | 48 Participants |
| Indication for induction Oligohydramnios/Polyhydramnios | 21 Participants | 22 Participants | 43 Participants |
| Indication for induction Others | 18 Participants | 22 Participants | 40 Participants |
| Indication for induction Post-EDC | 21 Participants | 21 Participants | 42 Participants |
| Indications for cesarean delivery Arrest of descent | 5 Participants | 4 Participants | 9 Participants |
| Indications for cesarean delivery Arrest of dilation | 9 Participants | 6 Participants | 15 Participants |
| Indications for cesarean delivery Failed induction of labor | 3 Participants | 1 Participants | 4 Participants |
| Indications for cesarean delivery Non-reassuring Fetal tracing | 20 Participants | 19 Participants | 39 Participants |
| Indications for cesarean delivery Others | 1 Participants | 0 Participants | 1 Participants |
| Insurance Private | 59 Participants | 53 Participants | 112 Participants |
| Insurance Service | 41 Participants | 47 Participants | 88 Participants |
| Mode of delivery Cesarean Delivery | 38 Participants | 30 Participants | 68 Participants |
| Mode of delivery Forceps Vaginal Delivery | 2 Participants | 1 Participants | 3 Participants |
| Mode of delivery Spontaneous Vaginal Delivery | 48 Participants | 59 Participants | 107 Participants |
| Mode of delivery Vacuum Vaginal Delivery | 12 Participants | 10 Participants | 22 Participants |
| Parity Multiparous | 26 Participants | 30 Participants | 56 Participants |
| Parity Nulliparous | 74 Participants | 70 Participants | 144 Participants |
| Sex: Female, Male Female | 100 Participants | 100 Participants | 200 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 100 | 0 / 100 |
| other Total, other adverse events | 0 / 100 | 0 / 100 |
| serious Total, serious adverse events | 0 / 100 | 0 / 100 |
Outcome results
Per Treatment Protocol: Time (Hours) From Induction to Delivery
Time frame: day 1
Population: those participants on treatment protocol
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Misoprostol Group | Per Treatment Protocol: Time (Hours) From Induction to Delivery | 20.5109 hours | Standard Deviation 10.09 |
| Misoprostol and Foley Bulb Group | Per Treatment Protocol: Time (Hours) From Induction to Delivery | 16.6814 hours | Standard Deviation 7.47 |
The Time Interval From Induction to Delivery: All Participants
During labor from the start of the induction to the delivery
Time frame: Day 1
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Misoprostol Group | The Time Interval From Induction to Delivery: All Participants | 20.97 hours | Standard Deviation 10.27 |
| Misoprostol and Foley Bulb Group | The Time Interval From Induction to Delivery: All Participants | 16.27 hours | Standard Deviation 7.6 |
Time From Induction to Delivery: CD
Time (hours) from induction to delivery: Cesarean Delivery (CD)
Time frame: Day 1
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Misoprostol Group | Time From Induction to Delivery: CD | 24.38 hours | Standard Deviation 12.49 |
| Misoprostol and Foley Bulb Group | Time From Induction to Delivery: CD | 17.95 hours | Standard Deviation 9.29 |
Time From Induction to Delivery: VD
Time (hours) from induction to delivery: Vaginal Delivery (VD)
Time frame: Day 1
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Misoprostol Group | Time From Induction to Delivery: VD | 18.87 hours | Standard Deviation 8 |
| Misoprostol and Foley Bulb Group | Time From Induction to Delivery: VD | 15.55 hours | Standard Deviation 6.7 |
Time (Hours) From Induction to Delivery: Multiparous
Time frame: Day 1
Population: for nulliparous participants
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Misoprostol Group | Time (Hours) From Induction to Delivery: Multiparous | 15.99 hours | Standard Deviation 7.4 |
| Misoprostol and Foley Bulb Group | Time (Hours) From Induction to Delivery: Multiparous | 11.89 hours | Standard Deviation 4.6 |
Time (Hours) From Induction to Delivery: Nulliparous
Time frame: Day 1
Population: for nulliparous participants
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Misoprostol Group | Time (Hours) From Induction to Delivery: Nulliparous | 22.7 hours | Standard Deviation 10.58 |
| Misoprostol and Foley Bulb Group | Time (Hours) From Induction to Delivery: Nulliparous | 18.15 hours | Standard Deviation 7.87 |
Estimated Blood Loss
Time frame: Day 1
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Misoprostol Group | Estimated Blood Loss | 493.3 ml | Standard Deviation 274 |
| Misoprostol and Foley Bulb Group | Estimated Blood Loss | 490.5 ml | Standard Deviation 304.1 |
Incidence of Chorioamnionitis
Time frame: Day 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Misoprostol Group | Incidence of Chorioamnionitis | 8 Participants |
| Misoprostol and Foley Bulb Group | Incidence of Chorioamnionitis | 4 Participants |
Incidence of Patient Discomfort
Time frame: Day 1
Population: data not collected
Incidence of Uterine Tachysystole
Time frame: Day 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Misoprostol Group | Incidence of Uterine Tachysystole | 12 Participants |
| Misoprostol and Foley Bulb Group | Incidence of Uterine Tachysystole | 6 Participants |
The Time From Active Phase to Delivery
Time frame: Day 1
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Misoprostol Group | The Time From Active Phase to Delivery | 3.11 hours | Standard Deviation 2.75 |
| Misoprostol and Foley Bulb Group | The Time From Active Phase to Delivery | 3.76 hours | Standard Deviation 3 |
The Time From Induction Until to Active Phase Labor
Time frame: Day 1
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Misoprostol Group | The Time From Induction Until to Active Phase Labor | 17.43 hours | Standard Deviation 8.6 |
| Misoprostol and Foley Bulb Group | The Time From Induction Until to Active Phase Labor | 12.81 hours | Standard Deviation 5.83 |